Form 4: Alkermes EVP Executes Planned Stock Transactions

Craig C. Hopkinson, Alkermes plc's EVP R&D and Chief Medical Officer, executed a pre-arranged 10b5-1 plan, exercising stock options and subsequently selling ordinary shares.

Summary

• Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reported transactions involving the company's ordinary shares.
• On October 15, 2025, Hopkinson exercised employee stock options to acquire 5,000 ordinary shares at an exercise price of $19.34 per share.
• Concurrently, on October 15, 2025, he sold 9,000 ordinary shares at a weighted average price of $31.5307 per share. The sales occurred in multiple transactions ranging from $31.51 to $31.60.
• Both the option exercise and the subsequent sale were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025.
• Following these transactions, Hopkinson's direct beneficial ownership of ordinary shares is 73,740.
• He also holds 45,104 unexercised employee stock options, which are fully vested.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions executed under a pre-arranged 10b5-1 plan, which is a neutral event from a sentiment perspective. It reflects personal financial management rather than a direct statement on company performance or outlook.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to managing personal holdings rather than opportunistic trading.
• The executive monetized vested stock options, which is a common and expected part of executive compensation, reflecting value derived from prior grants.

Negatives

• The sale of 9,000 shares by a key executive, even under a 10b5-1 plan, represents a reduction in direct ownership, which some investors might interpret as a lack of conviction, though this is often a personal financial planning decision.

Risks

• No specific risks are mentioned in this Form 4 filing, as it primarily reports insider transactions.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common across all industries as executives manage their personal finances and diversify their holdings. This specific transaction does not provide broader industry insights.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting an insider transaction. The use of a Rule 10b5-1 plan aligns with best practices for corporate governance, providing transparency and mitigating concerns about opportunistic insider trading. There are no specific comparable companies or projects mentioned in this filing to assess against industry benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock ownership changes, which can be a factor in investment decisions, though these transactions are routine under a 10b5-1 plan.
• Employees: No direct impact on employees.
• Customers: No direct impact on customers.
• Suppliers: No direct impact on suppliers.
• Creditors: No direct impact on creditors.

Next Steps

• No specific future actions, events, or milestones for the company are mentioned in this insider transaction report.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction by an Alkermes executive, involving the exercise of stock options and subsequent sale of shares under a pre-arranged Rule 10b5-1 trading plan. Such transactions are typically for personal financial management and diversification, rather than a reflection of a change in the company's fundamental outlook. While insider selling can sometimes be viewed negatively, the pre-planned nature mitigates concerns about opportunistic timing. Therefore, this filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, as it does not indicate a significant shift in the company's prospects.

Keywords

Alkermes, ALKS, Insider Trading, Form 4, Stock Options, Executive Compensation, Share Sale, Rule 10b5-1 Plan, Craig C. Hopkinson